Drug Approval | January 28, 2022
European Commission approves Merck’s KEYTRUDA as adjuvant therapy for RCC
KEYTRUDA is now approved as monotherapy for adults with Renal Cell Carcinoma (RCC)
KEYTRUDA is now approved as monotherapy for adults with Renal Cell Carcinoma (RCC)
SOLOSEC is designed to be easy to take and one oral dose contains a complete course of treatment
This will evaluate the immunogenicity, safety, and reactogenicity of a single booster dose in adults aged 18 years and older
Evrysdi is approved in 70 countries and submitted in a further 31 with more than 4,500 patients treated to date
Merck is studying the Complete Response Letter and it is not related to the safety of gefapixant
First participants enrolled in clinical trial received Omicron-based vaccine candidate as a two-dose primary series and as a booster dose
Previously, the use of the drug was limited to patients requiring hospitalization
UCB plans to submit regulatory applications in Q3 2022
Quviviq is a dual orexin receptor antagonist, which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness, as opposed to treatments that generally sedate the brain
Vigabatrin is an anticonvulsant. It is known to work by stopping the breakdown of a natural calming substance (GABA) in the brain
Subscribe To Our Newsletter & Stay Updated
